Suppressive Effect of 19-nor-1alpha-25-Dihydroxyvitamin D2 on Gastric Cancer Cells and Peritoneal Metastasis Model.
10.3346/jkms.2012.27.9.1037
- Author:
Mi Ra PARK
1
;
Ji Hee LEE
;
Myung Suk PARK
;
Jun Eul HWANG
;
Hyun Jeong SHIM
;
Sang Hee CHO
;
Ik Joo CHUNG
;
Woo Kyun BAE
Author Information
1. Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea. drwookyun@jnu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Paricalcitol (19-nor-1alpha-25-dihydroxyvitamin D2);
Stomach;
Neoplasms;
Apoptosis
- MeSH:
Animals;
Antineoplastic Agents/chemistry/*pharmacology/therapeutic use;
Apoptosis/drug effects;
Cell Cycle Checkpoints/drug effects;
Cell Cycle Proteins/metabolism;
Cell Line, Tumor;
Cell Proliferation/drug effects;
Disease Models, Animal;
Ergocalciferols/chemistry/*pharmacology/therapeutic use;
Fluorodeoxyglucose F18/chemistry/diagnostic use;
Humans;
Mice;
Mice, Inbred BALB C;
Peritoneal Neoplasms/drug therapy/*secondary;
Positron-Emission Tomography;
Stomach Neoplasms/drug therapy/*pathology;
Transplantation, Heterologous
- From:Journal of Korean Medical Science
2012;27(9):1037-1043
- CountryRepublic of Korea
- Language:English
-
Abstract:
The active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), inhibits the growth of several types of human cancer cells in vitro, but its therapeutic use is limited because it causes hypercalcemia. Among its analogs, 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol), has fewer calcemic effects and exhibits an activity equipotent to that of calcitriol. We assessed the antitumor and anti-inflammatory effects of paricalcitol in gastric cancer cells, and evaluated the potential role of vitamin D in the treatment of peritoneal metastatic gastric cancer. In this study, treatment with paricalcitol inhibited gastric cancer cell growth and induced cell cycle arrest. Paricalcitol also induced apoptosis and showed anti-inflammatory activity. Moreover, the growth of intraperitoneal metastases in vivo was reduced in mice treated with paricalcitol. 18F-FDG uptake was significantly lower in the paricalcitol group compared to control group (SUV; control group 13.2 +/- 5.3 vs paricalcitol group 4.5 +/- 3.0). Intraperitoneal tumor volume was significantly lower in paricalcitol treated mice (control group 353.2 +/- 22.9 mm3 vs paricalcitol group 252.0 +/- 8.4 mm3). These results suggest that the vitamin D analog, paricalcitol, has anticancer activity on gastric cancer cells by regulation of the cell cycle, apoptosis, and inflammation.
